Eli Lilly is predicting strong sales and profit growth in 2026, seemingly shrugging off the pricing pressure that weighed ...

Luke Miels' first financial results since taking over as chief executive of GSK revealed a jump in sales and profits, fuelled by HIV, cancer and respiratory medicines.

Looking ahead to 2026, Doustdar said Novo Nordisk had high expectations for the potential launches of new incretin ...

The loss of market exclusivity for a trio of big-selling drugs in the last quarter of 2025 dragged down Novartis sales, but ...

"The government has claimed that the deal will only cost around £1 billion per year, but the UK's new commitment to double ...

There’s no doubt that large language models and generative AI tools have taken the world by storm. Their ability to create, ...

Wave Life Sciences has lost GSK as the partner for its RNA-editing drug for alpha-1 antitrypsin deficiency (AATD), just over ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Lisa Sims, executive director of learning strategy & ...

AstraZeneca's new formulation of systemic lupus erythematosus (SLE) therapy Saphnelo has been turned down by the FDA, despite getting the go-ahead in Europe a few weeks ago.

ICH E6 (R3) introduces a dedicated section on data governance, reflecting the increasing complexity of data sources and ...

Novo Nordisk is considering additional regulatory filings for CagriSema – already submitted in the US for obesity – after the drug outperformed Ozempic in a head-to-head diabetes study.

Two months later, the institute launched the Standardized Organoid Modeling Center, a national initiative financed with an initial commitment of $87 million over three years, intended to improve the ...